SYK STRYKER CORPORATION

Stryker announces intention to nominate Manny Maceda to board of directors

Stryker announces intention to nominate Manny Maceda to board of directors

Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025.

Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and CEO from 2018 to 2024. In that role, he led Bain’s global strategy and operations across more than 50 offices, driving the firm’s transformation to strengthen digital capabilities, expand its focus on sustainability, and preserve its award-winning culture.

Since joining Bain in 1989, Maceda has held multiple senior leadership roles and advised CEOs across a wide range of industries on enterprise-wide initiatives spanning strategy, growth, cost management, and organizational effectiveness.

He holds a Master of Science in Management from the MIT Sloan School of Management where he serves on the advisory board, and a bachelor’s degree in chemical engineering, with High Honors, from the Illinois Institute of Technology.

“We look forward to the potential of adding Manny to our Board,” said Kevin Lobo, Chair and CEO, Stryker. “His strategic acumen, global leadership experience and track record in transformation will enhance the Board as we grow, evolve and create long-term value for shareholders.”

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at .

Contacts

For investor inquiries:

Jason Beach, Vice President, Investor Relations at 269-385-2600 or  

For media inquiries:

Kim Montagnino, Vice President, Global Communications at 269-385-2600

or



EN
26/03/2025

Underlying

SYKSTRYKER CORPORATION

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRYKER CORPORATION

Free Trial
SYK STRYKER CORPORA...

Stryker Corp: 1 director

A director at Stryker Corp sold 1,241 shares at 388.560USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

SYK STRYKER CORPORATION
05/14/25 May 14, 2025 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker declares an $0.84 per share quarterly dividend

Stryker declares an $0.84 per share quarterly dividend Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in ...

May 8, 2025 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker reports first quarter 2025 operating results

Stryker reports first quarter 2025 operating results Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Org...

May 1, 2025 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker to participate in the Bank of America Securities 2025 Global H...

Stryker to participate in the Bank of America Securities 2025 Global Healthcare Conference Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Preston Wells, Vice President and Chief Financial Officer, and Jason Beach, Vice President, Finance and Investor Relations. Their presentation is scheduled for 1:40 p.m. Pacific Time. A live webcast and replay of the presentation will ...

April 29, 2025 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker to announce financial results for its first quarter of fiscal ...

Stryker to announce financial results for its first quarter of fiscal year 2025 Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results.  ...

April 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch